Lyophilization or freeze drying is the process, in which the water content in the drug sample is frozen, followed by its removal from the sample. In the process of lyophilization, the frozen water content changes directly from solid to vapor without passing through a liquid phase. The process includes three steps: Freezing, primary drying (sublimation), and secondary drying (desorption). Pharmaceutical products that undergo lyophilization process include bulk pharmaceutical/biopharmaceutical ingredient (API), protein, collagen, peptide, oligonucleotide, enzymes, and mAbs.
Market Dynamics
Lyophilized drugs are majorly used to treat infectious diseases and autoimmune diseases. Thus, increasing prevalence of infectious diseases is expected to aid in growth of the global lyophilized drugs market. For instance, according to The Lancet Infectious Diseases (report) published in 2017, fungal infection affects over a billion people worldwide, resulting in around 11.5 million life-threatening infections and over 1.5 million deaths, annually. The number of lyophilized drugs such as Amphotericin B (Mycoflu), Vonfung NDD (voriconazole,) and other antifungal lyophilized drugs are available in market for treating fungal infections.
Lyophilized drug manufacturers are looking forward to expand their facilities to produce lyophilized drugs on large scale, which in turn contributing to growth of the global lyophilized drugs market. For instance, on January 2017, AB Technologies (AB) announced investment of US$ 10.5 million to build a new 23,000-square-foot manufacturing facility at its site in Bloomington, Indiana. The new facility will include manufacturing area for formulating, filling, lyophilizing, and packaging drugs for early-phase clinical trial studies. Moreover, AB Technologies (AB) added aseptic filling and lyophilizer loading systems into the new facility.
Major pharmaceutical manufacturers are engaged in the development and launching of innovative lyophilized drugs, which is expected to drive the global lyophilized drugs market growth. For instance, in November 2018, Xellia Pharmaceuticals launched Vancomycin Hydrochloride for Injection, USP within the U.S. market. Vancomycin Hydrochloride for Injection is lyophilized powder to treat or prevent infections that are caused by bacteria
Key features of the study:
- This report provides in-depth analysis of the global lyophilized drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global lyophilized drugs market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Sanofi S.A, Merck & Co., Inc., Fresenius Kabi USA, LLC., Ciron Drugs & Pharmaceuticals Pvt Ltd., GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC, Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.), and BTG Plc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global lyophilized drugs market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global Lyophilized Drugs Market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Lyophilized Drugs Market, By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- Global Lyophilized Drugs Market, By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- Global Lyophilized Drugs Market, By Packaging Type:
- Global Lyophilized Drugs Market, By Region:
- North America
- By Country:
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Middle East
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID’s
- Others
- By Indication:
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Cancer
- Others
- By Packaging Type:
- Company Profiles
- Sanofi S.A *
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co., Inc.
- Fresenius Kabi USA, LLC.
- Ciron Drugs & Pharmaceuticals Pvt Ltd.
- GlaxoSmithKline plc.
- Mylan NV.
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.)
- BTG Plc.
“*” marked represents similar segmentation in other categories in the respective section.
